{
    "nctId": "NCT02610413",
    "briefTitle": "Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer",
    "officialTitle": "Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 354,
    "primaryOutcomeMeasure": "Identification of rare coding variants of large effect that predict the risk of bevacizumab-induced hypertension",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* European American patients with deoxyribonucleic acid (DNA) available and designated case or control\n* Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab\n* Patients who did not develop hypertension following a full course of treatment with bevacizumab",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}